These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12352941)

  • 21. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
    Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T
    AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    Sathia L; Obiorah I; Taylor G; Kon O; O'Donoghue M; Gibbins S; Walsh J; Winston A
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):897-901. PubMed ID: 18671475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
    Poirier JM; Robidou P; Jaillon P
    Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
    Maartens G; Boffito M; Flexner CW
    Curr Opin HIV AIDS; 2017 Jul; 12(4):355-358. PubMed ID: 28403028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
    Maartens G; Decloedt E; Cohen K
    Antivir Ther; 2009; 14(8):1039-43. PubMed ID: 20032533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
    Scarsi KK; Smeaton LM; Podany AT; Olefsky M; Woolley E; Barr E; Pham M; Mawlana S; Supparatpinyo K; Gatechompol S; Jalil EM; Gadama L; Badal-Faesen S; Belaunzaran-Zamudio PF; Godfrey C; Cohn SE; Mngqibisa R;
    Contraception; 2023 May; 121():109951. PubMed ID: 36641094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy.
    Langmann P; Schirmer D; Väth T; Zilly M; Klinker H
    J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):151-6. PubMed ID: 11393699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
    Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
    Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
    Veldkamp AI; van Heeswijk RP; Meenhorst PL; Mulder JW; Lange JM; Beijnen JH; Hoetelmans RM
    J Chromatogr B Biomed Sci Appl; 1999 Oct; 734(1):55-61. PubMed ID: 10574190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings.
    Semvua HH; Kibiki GS; Kisanga ER; Boeree MJ; Burger DM; Aarnoutse R
    Ther Drug Monit; 2015 Feb; 37(1):22-32. PubMed ID: 24943062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
    Uttayamakul S; Likanonsakul S; Manosuthi W; Wichukchinda N; Shioda T; Khusmith S
    Southeast Asian J Trop Med Public Health; 2012 Jan; 43(1):78-88. PubMed ID: 23082557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
    Almond LM; Hoggard PG; Edirisinghe D; Khoo SH; Back DJ
    J Antimicrob Chemother; 2005 Oct; 56(4):738-44. PubMed ID: 16141277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.
    Manfredi R; Calza L; Chiodo F
    J Antimicrob Chemother; 2002 May; 49(5):723-9. PubMed ID: 12003964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-performance liquid chromatography method for analyzing the antiretroviral agent efavirenz in human plasma.
    Villani P; Pregnolato M; Banfo S; Rettani M; Burroni D; Seminari E; Maserati R; Regazzi MB
    Ther Drug Monit; 1999 Jun; 21(3):346-50. PubMed ID: 10365651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
    Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
    J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
    Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
    Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
    Titier K; Lagrange F; Péhourcq F; Edno-Mcheik L; Moore N; Molimard M
    Ther Drug Monit; 2002 Jun; 24(3):417-24. PubMed ID: 12021635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.